Enhertu OK ends 10-year EU gap in frontline breast cancer
Enhertu plus Perjeta has become the first new frontline therapy approved for advanced HER2-positive breast cancer in the EU for over a decade.
Roche taps Simcere for autoimmune trispecific for $1.53bn
Roche is paying $75m upfront for a trispecific drug developed by China's Simcere Zaiming for B-cell-mediated autoimmune disorders and blood cancers.
Decarbonising respiratory care requires a new kind of generi...
Generics manufacturers have long played a critical role in supporting the sustainability of the NHS, delivering affordable medicines at scale, expanding patient access, and helping healthca
Specialty medication access hinges on a 48-hour window
The vast majority of healthcare providers (HCPs) say that PA-related delays directly harm patient outcomes.
Featured Content
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
World Novel Drug Discovery Summit South Korea
Korea’s First Industry Forum Driving Best-in-Class Discovery for Next-Generation Modalities
2nd World-RNA Based Therapeutics & Vaccines Summit South Kor...
Korea’s Forum to Advance mRNA, CircRNA & saRNA Medicines for Clinical & Commercial Readiness
AI, Forecasting, Insights and Analytics for Smarter Decision...
Learn from case studies, expert-led panels, roundtable discussions, and interactive workshops on Gen AI-powered forecasting
30th Portfolio Decision-Making & Prioritisation for Pharma
Pharmaceutical portfolio decision-making is facing structural pressure.
R&D Governance, Controlling and Innovation for Pharma
The Marcus Evans R&D Governance, Controlling, and Innovation for Pharma conference will take place at the Crowne Plaza - Frankfurt Congress Hotel